Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With Narcolepsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Diagnosis and Criteria for Inclusion:~Patients are included in the study if all of the following criteria are met:~* Written informed consent is obtained~* The patient is an outpatient, man or woman of any ethnic origin, 18 to 65 years of age (inclusive)~* The patient has a complaint of excessive sleepiness~* The patient has a current diagnosis of narcolepsy according to ICSD criteria.~* The patient is in good health as determined by a medical and psychiatric history, physical examination, electrocardiogram (ECG), and serum chemistry, hematology, and urinalysis.~* Women must be surgically sterile, 2 years postmenopausal, or, if of child-bearing potential, using a medically accepted method of birth control (ie, barrier method with spermicide, steroidal contraceptive \[oral, implanted, and Depo-Provera contraceptives must be used in conjunction with a barrier method\], or intrauterine device \[IUD\]) and agree to continued use of this method for the duration of the study.~* The patient has a mean sleep latency of 6 minutes or less as determined by the Multiple Sleep Latency Test (MSLT) (performed at 0900, 1100, 1300, and 1500).~* The patient has a CGI-S (Clinical Global Impression of Severity of Illness) rating of 4 or more.~* The patient does not have any medical or psychiatric disorders that could account for the excessive daytime sleepiness.~* The patient is able to complete self rating scales and computer-based testing.~* The patient is willing and able to comply with study restrictions and to attend regularly scheduled clinic visits as specified in this protocol.~Criteria for Exclusion:~Patients are excluded from participating in this study if 1 or more of the following criteria are met. The patient:~* has any clinically significant, uncontrolled medical or psychiatric conditions (treated or untreated)~* has a probable diagnosis of a current sleep disorder other than narcolepsy~* consumed caffeine including coffee, tea and/or other caffeine containing beverages or food averaging more than 600 mg of caffeine per day~* used any prescription drugs disallowed by the protocol or clinically significant use of over the-counter (OTC) drugs within 7 days before the second screening visit~* has a history of alcohol, narcotic, or any other drug abuse as defined by the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association, 4th Edition (DSM IV)~* has a positive UDS at the screening visit, without medical explanation~* has a clinically significant deviation from normal in the physical examination~* is a pregnant or lactating woman. (Any woman becoming pregnant during the study will be withdrawn from the study.)~* has used an investigational drug within 1 month before the screening visit~* has any disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery)~* has a known clinically significant drug sensitivity to stimulants or modafinil

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Armodafinil 250 mg
- 2 (Type: EXPERIMENTAL): Armodafinil 150 mg
- 3 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).